广生堂：公司将继续稳步推进相关乙肝创新药临床研发工作

Core Viewpoint - The report presented at the AASLD annual meeting is a significant showcase of the company's progress in innovative drug development for hepatitis B treatment, aimed at gaining international attention in the field of hepatology and fostering friendly international exchanges and discussions [1] Group 1 - The company is committed to steadily advancing the clinical research and development of innovative hepatitis B drugs [1] - The company will fulfill its obligation to disclose information regarding the progress of innovative drugs in a timely manner, in accordance with regulations [1]